• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PULSE ALERT: Bragar Eagel & Squire, P.C. is Investigating Pulse Biosciences, Inc. on Behalf of Pulse Stockholders and Encourages Investors to Contact the Firm

By: Bragar Eagel & Squire, P.C. via Business Wire
February 11, 2022 at 21:00 PM EST

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Pulse Biosciences, Inc. (“Pulse” or the “Company”) (NASDAQ: PLSE) on behalf of Pulse stockholders. Our investigation concerns whether Pulse has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On February 8, 2022, Pulse issued a press release “announc[ing] an update to its recent U.S. Food and Drug Administration (FDA) 510(k) submission to add the specific indication for treatment of sebaceous hyperplasia to expand the CellFX System’s current labeling.” Specifically, Pulse advised that following its submission of “ a 510(k) in December 2021 to add the treatment of sebaceous hyperplasia to the CellFX System’s indications for use in the United States”, “ [o]n February 5, 2022, the Company received an Additional Information (“AI”) letter from the FDA”, in which “the FDA stated it did not believe the Company provided sufficient clinical evidence at this time to support the expanded indication for use, and that the Company had not met the primary endpoints of the sebaceous hyperplasia FDA-approved IDE study.”

On this news, Pulse’s stock price fell $3.74 per share, or 34.44%, to close at $7.12 per share on February 8, 2022.

If you purchased or otherwise acquired Pulse shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220211005517/en/

Contacts

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Alexandra B. Raymond, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com

More News

View More
Fluence Energy Could Be a Multi-Bagger Play in Energy Technology
Today 7:24 EDT
Via MarketBeat
Tickers FLNC GS
After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
October 14, 2025
Via MarketBeat
Tickers AEM B BAC GDX GDXJ GLD
Buyback Boom: 3 Companies Betting Big on Themselves
October 14, 2025
Via MarketBeat
Tickers AZO ESTC LMT
Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
October 14, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers DELL MSFT
Amazon Is on the Cusp of Becoming a Grocery Disruptor
October 14, 2025
Via MarketBeat
Tickers ACI AMZN COST KR WMT
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.19
+0.00 (0.00%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap